Who
Liam Ratcliffe
Director
Company insider
Files Form 4 as: Director, OnKure Therapeutics; Director, Disc Medicine; Director, Upstream Bio; Director, Climb Bio; Director, Arvinas; Director, Passage Bio; Director, Cogent Biosciences; Director and 10% owner, Aptinyx.
In numbers
- Trades disclosed
- 141
- Buys
- 9
- Sells
- 18
- Bought
- $68.4M
- Sold
- $71.6M
- Companies
- 13
- Companies where not an officer
- 13
- First trade
- 24 Oct 2012
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,275 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,275 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 10 Oct 2024filed 15 Oct 2024 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 26 Jun 2024filed 28 Jun 2024 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 Jun 2023filed 9 Jun 2023 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,136 at $0.00 | filing |
| 18 May 2023filed 22 May 2023 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 Dec 2022filed 3 Jan 2023 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,192 at $0.00 | filing |
| 19 May 2022filed 1 Jun 2022 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?COGT · insidermonkey.com · 20 Oct 2026Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Liam Ratcliffe; 2 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.